TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25414475
Drug: Benztropine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (2 mg intramuscular)
Study: 21903010
Drug: Comprehensive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive physical therapy (PT)
Study: 11315533
Drug: Conjoint family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint family therapy and eclectic approach
Study: 8952239
Drug: Intraoral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral lidocaine patches
Study: 6996784
Drug: Pseudoephedrine and
Normalized name: Pseudoephedrine and terfenadine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine and triprolidine combination
Study: 31791405
Drug: Interactive tablet-based
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive tablet-based education intervention
Study: 22443058
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (8 mg daily of ferric pyrophosphate and ferrous fumarate)
Study: 18713232
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate 1 g twice per day
Study: 11840097
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% saline
Study: 10803112
Drug: Hytac (HY)
Normalized name: chlorpheniramine tannate / hydrocodone tannate Extended Release Suspension [HyTan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hytac (HY) with both polymerization modes without preparation
Study: 10803112
Drug: Dyract (DY)
Normalized name: dextromethorphan hydrobromide Disintegrating Oral Tablet [Duract Cough]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyract (DY) with softstart-polymerization (SSP) without preparation
Study: 29250843
Drug: Cinnamon powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon powder capsules 1.5 g/day in 3 divided doses for 12 weeks
Study: 31621982
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment
Study: 15175561
Drug: Nifedipine capsules
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsules (2 x 10 mg doses given q8h for a total of three doses)
Study: 15175561
Drug: Nifedipine prolonged
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine prolonged action tablets (20 mg doses given q12h for a total of two doses)
Study: 15175561
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS tablet (60 mg single dose)
Study: 8470059
Drug: Heparin (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (small amounts detected in AT-III concentrates)
Study: 31281181
Drug: FA +
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA + L-thyroxine
Study: 27891160
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment
Study: 11298132
Drug: No antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiretroviral treatment
Study: 3528718
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no human albumin therapy)
Study: 27633174
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus casei Shirota)
Study: 21346616
Drug: Quetiapine 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 1200 mg/d
Study: 21733490
Drug: Quetiapine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 800 mg/d
Study: 9350607
Drug: Vancomycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (5 mg/kg/day bid)
Study: 9350607
Drug: Teicoplanin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (5 mg/kg/day once daily)
Study: 29125700
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (2 × 25 mg)
Study: 29125700
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D (2 × 12.5 mg)
Study: 29125700
Drug: Formulation E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation E (2 × 12.5 mg)
Study: 29125700
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (1 × 25 mg) under fed conditions
Study: 22305026
Drug: 4 oz
Normalized name: Oval Amber 4 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 oz of cranberry juice daily
Study: 22305026
Drug: 8 oz
Normalized name: Ointment Jar 8 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 oz of cranberry juice daily
Study: 14578019
Drug: Apomorphine (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.005 mg/kg)
Study: 31725748
Drug: Nitrogen balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen balance measurement (g/24h)
Study: 30576544
Drug: Netupitant 300
Normalized name: netupitant 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netupitant 300 mg
Study: 24122871
Drug: Netupitant 450
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant 450 mg
Study: 24122871
Drug: [(14) C]‐netupitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(14) C]‐netupitant 300 mg (ADME study)
Study: 9471921
Drug: Chronic exposure
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic exposure to carbon disulphide (CS2) at concentrations of 9.36‐23.4 mg/m3
Study: 3315594
Drug: Intravenous anisoylated
Normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Study: 3315594
Drug: Heparin 5000U
Normalized name: HEPARIN NA BEEF 5000U/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000U
Study: 21091220
Drug: Irbesartan/HCTZ 150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ 150/12.5 mg
Study: 21091220
Drug: Valsartan/HCTZ 80/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ 80/12.5 mg
Study: 18220941
Drug: Aggrenox (antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggrenox (antiplatelet agent)
Study: 18220941
Drug: NXY (free
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY (free radical trapping agent)
Study: 18220941
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (for prevention of deep vein thrombosis post-stroke)
Study: 15121566
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg daily, oral)
Study: 15121566
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (intravenous)
Study: 9876475
Drug: High-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroid (prednisone or dexamethasone) during remission induction
Study: 9876475
Drug: Chemotherapy-maintained remission
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy-maintained remission
Study: 31822885
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (favipiravir and oseltamivir)
Study: 24632748
Drug: Oseltamivir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir monotherapy
Study: 25400284
Drug: Viagra (original)
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viagra (original) 100 mg
Study: 25400284
Drug: Edyfil (generic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edyfil (generic) 100 mg
Study: 19395984
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/d for 1 month, followed by a taper of 30 mg/d for 22 weeks)
Study: 16547904
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy (9 weekly one-hour sessions)
Study: 23109680
Drug: Nutrient-enriched formula
Normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient-enriched formula (treatment B)
Study: 23109680
Drug: Term formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Term formula (treatment A)
Study: 15608435
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.0 mg/day, pyridoxine 25 mg/day, and cobalamin 0.5 mg/day (active VITATOPS medication)
Study: 18566295
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg/d)
Study: 2669998
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (S)
Study: 2669998
Drug: Standard plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plus intermediate-dose methotrexate (SAM)
Study: 22921481
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment (10mg/day initially, increased to 10-20mg/day)
Study: 12454840
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/day
Study: 19457141
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/day (nonresponders who entered rollover study ETV-901)
Study: 14627785
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 mg/kg/week
Study: 14627785
Drug: Efalizumab 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 2 mg/kg/week
Study: 14627785
Drug: Efalizumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (after discontinuation at week 24)
Study: 16786816
Drug: Brief Strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Strategic Family Therapy (BSFT) for 12 weeks
Study: 10371474
Drug: Cefazolin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin, 1 g/1,000 mL, amnioinfusion
Study: 8688279
Drug: Colloid (polygeline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid (polygeline, Haemaccel) 8 ml kg‐1 (n = 15)
Study: 29038320
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (2 doses at 12-24 months)
Study: 18591547
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily)
Study: 26802155
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg b.i.d.)
Study: 26802155
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of selumetinib (150 mg daily) with erlotinib (100 mg daily)
Study: 24581940
Drug: Control-dose conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-dose conformal radiotherapy (64 Gy in 32 fractions)
Study: 24581940
Drug: Escalated-dose conformal
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated-dose conformal radiotherapy (74 Gy in 37 fractions)
Study: 21877138
Drug: Chained sequential
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chained sequential operations
Study: 17296878
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with good INR control (>75%)
Study: 27137148
Drug: Quetiapine 25
Normalized name: quetiapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 25 mg immediate-release tablets
Study: 20593742
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch
Study: 20502014
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules
Study: 19272499
Drug: Four different
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four different gel formulations
Study: 7935815
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride (beta-adrenergic receptor antagonist)
Study: 2232919
Drug: Monitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring and feedback using an electronic device that records the time and day pills are removed
Study: 21767103
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (immediate therapy)
Study: 21767103
Drug: Delayed antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antiretroviral therapy (after decline in CD4 count or onset of symptoms)
Study: 17116721
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus plantarum L-137 (HK-LP) 10 mg daily for 12 weeks
Study: 14746696
Drug: Eradicating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradicating treatment with omeprazole, amoxicillin, and clarithromycin for 7 days (group A, n = 47)
Study: 14746696
Drug: Placebo, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, amoxicillin, and clarithromycin for 7 days (group B, n = 46)
Study: 11203593
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid treatment
Study: 11210244
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride treatment
Study: 11210244
Drug: EDTA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA treatment
Study: 26272524
Drug: CF threshold
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF threshold of >8 g
Study: 22689416
Drug: Intensive cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cholesterol-lowering therapy with pitavastatin (target LDL-C; 80 mg/dl)
Study: 22689416
Drug: Moderate cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate cholesterol-lowering therapy with pitavastatin (target LDL-C; 100 mg/dl)
Study: 21612319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelaic acid 5% and clindamycin 2% (AA-Clin)
Study: 12888870
Drug: Antithrombin infusions
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin infusions
Study: 12888870
Drug: No antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombin treatment (control)
Study: 10877248
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment with optimized doses based on skin pigmentation measurements
Study: 10877248
Drug: Conventional UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional UVB treatment regimen with fixed dose increments
Study: 27541029
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics
Study: 23807984
Drug: Gynofit (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynofit (vaginal and perineal dose)
Study: 21144773
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 1200 mg/day for 24 months
Study: 9053501
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 followed by cisplatin 100 mg/m2
Study: 9053501
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 followed by cisplatin 75 mg/m2
Study: 9053501
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Study: 8977598
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 micrograms twice daily
Study: 7952551
Drug: Terbutaline 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1,000 micrograms three times daily
Study: 29533368
Drug: YYSG (Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYSG (Chinese herbal medicine capsules)
Study: 22771050
Drug: AXOS 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXOS 4.8 g/d
Study: 22771050
Drug: AXOS 2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXOS 2.2 g/d
Study: 22771050
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/d AXOS)
Study: 16243127
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 20 mg plus metronidazole 0.75% topical lotion
Study: 16243127
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus metronidazole 0.75% topical lotion
Study: 8119599
Drug: Hemorheological manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemorheological manipulation including plasma expansion with hydroxyethyl-starch, withdrawal of whole blood if hematocrit was above 42%, and parenteral pentoxifylline.
Study: 2605993
Drug: Active marijuana
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active marijuana (0-2.7% delta 9 THC), 4 cigarettes smoked daily, 2 prior to and 2 during social access period.
Study: 786676
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of AN 448 t.i.d.
Study: 24884731
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol at 0.7 g/kg
Study: 24884731
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol at 1.0 g/kg
Study: 24884731
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol at 1.4 g/kg
Study: 11488118
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate solution
Study: 9460311
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with intravenous oxytocin
Study: 9460311
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with vaginal prostaglandin E2 gel
Study: 30727931
Drug: Direct Antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Antiviral Agents (DAAs), sofosbuvir-based therapies for 12 weeks
Study: 28930864
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg·d)
Study: 11159230
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg every 6 h
Study: 11159230
Drug: Metamizol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 1 g every 6 h
Study: 22584689
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g every 6 h
Study: 2906888
Drug: SASP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SASP (1 g, n = 21)
Study: 2906888
Drug: SAB (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAB (0.72 g, n = 22)
Study: 2044398
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg naftidrofuryl twice daily in slow-release form
Study: 31165457
Drug: Sugammadex (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (4 mg·kg−1)
Study: 31165457
Drug: Neostigmine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (40 µg)
Study: 27771984
Drug: Desflurane inhalation
Normalized name: Desflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane inhalation anesthesia (Group I)
Study: 27771984
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anesthesia with ischemic preconditioning (Group TIP)
Study: 26009577
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) plus standard therapy of intravenous methylprednisolone (IVMP)
Study: 26009577
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of intravenous methylprednisolone (IVMP)
Study: 16620355
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin lispro (0.075 U/kg/hour after a bolus of 0.15 U/kg IV regular insulin)
Study: 16620355
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin (bolus of 0.15 U/kg followed by infusion)
Study: 9226738
Drug: 20 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms/kg nicotine by nasal spray
Study: 9226738
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of nicotine
Study: 9226738
Drug: Generalization doses
Normalized name: albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalization doses
Study: 9226738
Drug: Confidence in
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence in discriminating training doses
Study: 7944440
Drug: Continuous arterial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous arterial infusion group